ELV Elevance Health, Inc.

Cambiar Opportunity Fund, managed by Cambiar Investors, published its Q2 2026 investor letter. The letter can be downloaded here. U.S. equity markets experienced a significant rebound in Q2, with the S&P 500 rising 15.2% and the Russell 2000 up 21.5%. Growth stocks outperformed value, although value retained a year-to-date lead. The market’s rise was fueled […]

UnitedHealth (UNH) stock trades at 22.5 times its past year's adjusted earnings, which are normalized net income with stock-based pay added back. That multiple leaves little room for error after three years of shrinking operating margins, sitting near the stock's 10-year median despite fundamentally weaker profitability. But the price looks different against the profit expected for fiscal 2026 and fiscal 2027. So what are UnitedHealth investors betting on.

UnitedHealth shareholders spent five years waiting for a stock that barely budged, yet something inside the company kept growing the whole time. Whether that something is enough to make UNH worth holding now depends on costs that management has not yet fully tamed.

With traders bracing for another possible 0.25% Fed hike in October, solid labor data and firm inflation keep pressure on anything seen as risky. Defensive dividend stocks suddenly feel less boring and more like a potential anchor for a jumpier market, especially for investors who care about steady income when policy stays tight. This article breaks down three large cap dividend payers exposed to these macro shocks and explores how the latest data may help or hurt each stock. The three...

If you own CVS Health (CVS), the primary focus shifts from 2026 execution toward potential headwind variables heading into 2027. Management raised its 2026 earnings outlook on its fiscal Q2 2026 call in August. It also gave an early read on 2027, a quarter sooner than usual. One warning in that read came with no number. Over the past three months, the shares lost 15.2%, while the S&P 500 gained 5.0%. What is the 2027 problem CVS would not put a number on.

By Exec Edge Editorial Staff Health insurance premiums have climbed for years. Deductibles have climbed right along with them. Yet a growing number of American households are choosing neither, opting instead for a decades-old alternative, which is not health insurance, built around monthly contributions and community values. “People are clearly paying high premiums now,” Liberty […] The post Liberty HealthShare’s Dorsey Morrow Makes the Financial Case for Healthsharing on Becker’s Healthcare Pod

UnitedHealth Group (UNH) stock has risen about 40% since late March 2026, against close to 19% for the S&P 500. Read cold, that looks like a recovery nobody could have timed. It was not hidden. The company had said plainly, months before the shares turned, that it would give up members to rebuild margin.

UnitedHealth (UNH) has turned its profits around. Operating earnings rose 55% in the second quarter of 2026, and management raised its full-year adjusted earnings guide to $19.50 to $20 a share. Revenue, though, has nearly stopped growing. So the rest of the recovery rests on something the company only partly controls: the medical bills of the people it insures.

Centene's robust cash flow is helping cut debt, with a lower debt-to-capital ratio and added liquidity reshaping its balance sheet.

Elevance Health has delivered a 1 year gain that puts the stock firmly on investors' radar, and the latest reaffirmed earnings outlook has only sharpened the focus on what you are paying for each dollar of profit. With the price around US$410.95 at the last close, the key issue now is whether that tag lines up with the insurer's earnings power. The stock is up 33.6% over the past year, which raises the question of whether that move is grounded in its underlying earnings profile. Management...

CVS Health (CVS) keeps a little over a penny of profit from every dollar it takes in. A net margin of 1.2% reads like a verdict on the business. On $415.1 billion of revenue, one point of net margin is worth over $4 billion, and 1.2% is closer to a floor than a peak. Management has been working on it through 2026.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

UnitedHealth's repair job is going to plan almost everywhere. The exception is the cost of its commercial health plans, where medical costs are running modestly above the 11% the company had been expecting. Medicare costs are coming in below what it planned for 2026, and Medicaid cost trend is in line, though management expects Medicaid margins to stay pressured for 2026. That cost divergence is what a holder should watch.

Here is how Elevance Health (ELV) and American Well Corporation (AMWL) have performed compared to their sector so far this year.

ELV vs. DHR: Which Stock Is the Better Value Option?

CVS Health's Health Services arm is gaining from pharmacy strength and improving care delivery, with robust new sales and clinic economics supporting growth.

The health care giant showered its owners with cash, yet the stock spent years in the slow lane. Here’s the accounting of what that trade-off actually delivered.

UnitedHealth (UNH) has spent the past year repairing margins rather than chasing growth. The shares rebounded well ahead of any actual margin recovery: up about 38% over the past six months, though down about 6% over the past three, and still behind the S&P 500 over the past twelve months, 12.2% for the stock against 18.6% for the index. What argues for owning them now shows up in cash running ahead of reported profit.

Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.

CNC is set to reshape its Medicare Advantage business around dual-eligible members and a simpler footprint to drive margin recovery.

Key Takeaways:Guidance Raised: Elevance Health lifted 2026 adjusted EPS guidance to at least $27, up from prior levels, after a strong Q2. Price Projection: Based on current execution, ELV stock could reach $494 by December 2028.

Elevance Health (ELV) has returned more than 40% over the past six months, though it is down 6.5% over the past three while the S&P 500 gained 3.4%. The next leg will not come from selling more insurance. It will come from keeping more of the premium it already collects.

UNH's TPG deal brings local support and investment to Florida WellMed clinics as Optum targets faster growth and stronger profitability.

Elevance Health Inc (NYSE:ELV) recently announced a total dividend of $1.72 per share, with the ex-dividend date set for 2026-09-10. For investors, the ex-dividend date is a critical marker: shareholders must own the stock before this date to qualify for the upcoming payment. As investors look forward to this next distribution, the spotlight also shines on the company's dividend history, yield, and growth rates.

UnitedHealth (UNH) runs the best operating margin of the three managed care companies in its peer group, and the slowest revenue growth of the three. It also carries a significant valuation premium over its peer, Cigna, trading at more than double its earnings multiple.

TPG just bought into the exact Optum clinics that derailed UnitedHealth's profits, and management is hours away from reaffirming guidance that could either validate the deal or reopen a wound investors hoped was healing.

What a time it’s been for Elevance Health. In the past six months alone, the company’s stock price has increased by a massive 47.7%, reaching $414.64 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Insurers spent the summer telling Wall Street exactly which Medicare Advantage plans are disappearing on December 31. Enrolled members get a letter in October, a closing enrollment window in December, and a rare legal protection most will never realize they have.

After a strong 37.5% return over the past year, Elevance Health now trades with a high value score and an undervalued read on market multiples, which raises the question of whether the recent share price strength has fully reflected that signal or not. Elevance Health has delivered a 37.5% 1 year return, so any further upside now depends on how much fundamental value is still not priced in. The appointment of Dr. Patrick Fox to lead Carelon Behavioral Services, alongside greater use of AI in...

UNH's 39% six-month rally reflects improving medical costs, stronger earnings estimates and a sharper focus on profitable businesses.

UnitedHealth (UNH) stock has gained about 41% since early March, and at roughly $400 a share the market has already paid for a recovery. The easy reading is that the turnaround is finished. It is not. One half got better over those six months, the other got worse, and the price reflects the good half.

UNH is showing signs of recovery as medical costs improve, Optum gains momentum and 2026 earnings guidance rises.

The market has crowned this healthcare giant the winner of its group, but a look at the underlying business raises the question of whether the celebration started too soon.

CNC's 117% rally now has support from improving margins, firmer pricing and higher earnings expectations, while valuation remains below key peers.

Elevance Health has underperformed its industry peers over the past year, but analysts are moderately optimistic about the stock’s prospects.

CNC's Marketplace recovery is boosting profitability as better pricing, medical cost trends and risk dynamics reshape its earnings outlook.

First Eagle Investment Management, an investment management company, released its Q2 2026 investor update for “First Eagle Global Fund”. The letter can be downloaded here. Easing tensions in the Middle East led to a strong rally in risk markets in Q2. The S&P 500 Index rose 15.2%, while the MSCI EAFE Index gained 10.8%. Growth […]

Hotchkis & Wiley, an investment management company, released its second-quarter 2026 investor letter for the “Large Cap Fundamental Value Fund.” A copy can be downloaded here. Equity markets posted strong returns, with the Russell 1000 Value Index rising by 13.9%, although many individual stocks lagged. Notably, semiconductor stocks and AI-related sectors saw exceptional gains. The rally […]

Consensus knocks a quarter off the health insurer's earnings multiple over two years, part of it measurement, and almost none of it from selling more coverage.

Its market-shock drawdowns have been ordinary in depth, and some of its longest waits back to the old high came after falls the index barely noticed.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how health insurance providers stocks fared in Q2, starting with Elevance Health (NYSE:ELV).

Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The healthcare giant sent a fortune back to its owners, but the market yawned. Here’s the real accounting of what that cash bought, and what it didn't.

CI's Smart Coverage links medical and supplemental benefits, offering up to $7,000 and automated claims for costly health events.

In recent weeks, Elevance Health has been highlighted for strong Q2 2026 results, raised full-year guidance, and operational gains driven by AI-enabled efficiency and cost savings. At the same time, the appointment of Dr. Patrick Fox to lead Carelon Behavioral Services underscores Elevance Health’s emphasis on behavioral health capabilities within its broader health services platform. Next, we’ll examine how Elevance’s AI-driven margin improvements and refreshed behavioral health leadership...

Elevance Health (ELV) drew fresh attention this week after its Carelon Behavioral Health unit appointed forensic psychiatrist Dr. Patrick Fox as leader, putting behavioral services for more than 61 million members under new oversight. Those leadership changes come as Elevance Health trades at US$398.87, with a 30 day share price return of 5.61% and year to date share price return of 12.60%. The 1 year total shareholder return of 31.36% contrasts with a 3 year total shareholder return that is...

Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund’s Investor Class (SSHFX) and Institutional Class (SSHVX) rose 10.48% and 10.58% in the second quarter of 2026, trailing the Russell 1000 Value Index’s 13.87% and the S&P […]

UNH outpaces ELV with stronger earnings prospects, improving Medicare profitability, greater upside and a more favorable risk-reward profile.

Dr. Patrick Fox, a forensic psychiatrist and health plan leader, will take the reins at Carelon Behavioral Services effective immediately. His experience will be “invaluable” for the unit, a top Elevance executive said.

Medicare's improvement is real but not a turn in cost trend, while commercial costs keep running higher and the margin fix there has slipped again.